Key result
Oral recombinant L. lactis delays death and yields ~60% relative survival in infected ducklings.
Why the study?
Duck hepatitis A virus type 1 and type 3 have been on the rise, seriously endangering duck farming.
Does oral administration of recombinant Lactococcus lactis co-expressing fusion VP1 protein of DHAV-1 and DHAV-3 prevent mortality in ducklings infected with DHAV-1 and DHAV-3?
Does oral administration of recombinant Lactococcus lactis co-expressing fusion VP1 protein of DHAV-1 and DHAV-3 prevent mortality in ducklings infected with DHAV-1 and DHAV-3?
Effect estimate: RPS 64.71%, 61.54%, and 57.89%
Oral administration of a recombinant L. lactis vaccine co-expressing VP1 proteins significantly improves survival and immune responses in ducklings challenged with DHAV-1 and DHAV-3.
May support oral L. lactis VP1 vaccines in ducklings; hypothesis-generating and requires validation before any practice change.
Duck viral hepatitis (DVH) is one of the most common diseases of waterfowl. Duck hepatitis A virus type 1 (DHAV-1) and type 3 (DHAV-3) have been on the rise seriously endangering the development of duck farming. In this study, we constructed a recombinant Lactococcus lactis (L. lactis) co-expressing the fusion VP1 protein of DHAV-1 and DHAV-3. Western blot and immunofluorescence analyses confirmed that the fusion VP1 protein was expressed on the cell surface of recombinant L. lactis stain. After immunization with the recombinant L. lactis by oral administration, the ducklings were challenged with highly pathogenic DHAV-1 and DHAV-3 by natural infection. The results showed that the recombinant L. lactis induced the specific IgG antibodies, and significantly increased the level of mucosal secretory immunoglobulin A (sIgA) and cytokines, such as interleukin-4 (IL-4), interleukin-10 (IL-10), and interferon gamma (IFN-γ). The immunized ducklings delayed death for around 4 days, and reduced mortality with the relative percent survival (RPS) being 64.71 %, 61.54 % and 57.89 % in DHAV-1, DHAV-3 and DHAV-1 + 3 infection group respectively. These results showed that the recombinant L. lactis constructed in this study provides a promising candidate for prevention and control of DHAV-1 and DHAV-3 infection.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied Duck viral hepatitis (DHAV-1 and DHAV-3 infection). Recombinant Lactococcus lactis co-expressing fusion VP1 protein of DHAV-1 and DHAV-3 was evaluated on Relative percent survival (RPS) (RPS 64.71%, 61.54%, and 57.89%). Oral administration of recombinant L. lactis expressing DHAV-1 and DHAV-3 VP1 protein delayed death by ~4 days and achieved relative percent survival of 57.89% to 64.71% in infected ducklings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: